Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130077 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas
A Phase 1 study, sponsored by James Felker.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01130077 is a Phase 1 study that has completed, run by James Felker. The registered enrollment target is 60 participants.
The verdict
NCT01130077, a Phase 1 study, has completed, sponsored by James Felker.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
Interventions
- BIOLOGICAL Poly-ICLC
- BIOLOGICAL HLA-A2 restricted glioma antigen peptides vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-02 |
| Est. Completion | 2024-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130077
The ClinicalTrials.gov registry entry for NCT01130077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Felker, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Poly-ICLC is the first listed.
NCT01130077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130077 about?
NCT01130077 is a clinical study titled "A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas". The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
What is the current status of trial NCT01130077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2009-02. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT01130077?
The interventions under investigation include: Poly-ICLC (BIOLOGICAL), HLA-A2 restricted glioma antigen peptides vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01130077?
This trial is sponsored by James Felker, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.